ABIVAX Société Anonyme 관리

관리 기준 확인 2/4

ABIVAX Société Anonyme CEO는 Marc M. de Garidel, May2023 에 임명되었습니다 의 임기는 1.42 년입니다. 총 연간 보상은 € 793.97K, 45.3% 로 구성됩니다. 45.3% 급여 및 54.7% 보너스(회사 주식 및 옵션 포함). 는 $ 383.78K 가치에 해당하는 회사 주식의 0.06% 직접 소유합니다. 383.78K. 경영진과 이사회의 평균 재임 기간은 각각 1.3 년과 3.2 년입니다.

주요 정보

Marc M. de Garidel

최고 경영자

€794.0k

총 보상

CEO 급여 비율	45.3%
CEO 임기	1.4yrs
CEO 소유권	0.06%
경영진 평균 재임 기간	1.3yrs
이사회 평균 재임 기간	3.2yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Marc M. de Garidel 의 보수는 ABIVAX Société Anonyme 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-€177m
Mar 31 2024	n/a	n/a	-€163m
Dec 31 2023	€794k	€359k	-€148m

보상 대 시장: Marc M. 의 총 보상 ($USD 857.05K ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 3.16M ).

보상과 수익: Marc M. 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Marc M. de Garidel (66 yo)

1.4yrs

테뉴어

€793,971

보상

Mr. Marc M. P. de Garidel, M.B.A., serves as Director of Claris Biotherapeutics, Inc. He serves as CEO at ABIVAX Société Anonyme since May 5, 2023 amd serves as its Director. He had been its Interim Chair...

리더십 팀

이름	위치	테뉴어	보상	소유권
Marc M. de Garidel	CEO & Director	1.4yrs	€793.97k	0.060% $ 383.8k
Philippe Pouletty	Founder & Director	no data	€35.00k	0.43% $ 2.8m
Didier Blondel	EVP, CFO & Board Secretary	7.8yrs	데이터 없음	0.00059% $ 3.8k
Didier Scherrer	Chief Scientific Officer	1.2yrs	데이터 없음	0.057% $ 359.9k
Patrick Malloy	Senior Vice President of Investor Relations	1.2yrs	데이터 없음	데이터 없음
Ida Hatoum	Chief People & Compliance Officer	1.3yrs	데이터 없음	데이터 없음
Pierre Courteille	Chief Business Officer	no data	데이터 없음	0% $ 0
Jerome Denis	Executive Vice President of Process Development & Manufacturing	1.1yrs	데이터 없음	데이터 없음
Michael Ferguson	Chief Commercial Officer	1.5yrs	데이터 없음	데이터 없음
Ana Sharma	VP & Global Head of Quality	less than a year	데이터 없음	데이터 없음
Hema Keshava	Senior Vice President of Finance	no data	데이터 없음	데이터 없음
Chris Rabbat	VP & Global Head of Medical Affairs	no data	데이터 없음	데이터 없음

1.3yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: AAVX.F 의 관리팀은 경험 (평균 재직 기간 1.3 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Marc M. de Garidel	CEO & Director	1.4yrs	€793.97k	0.060% $ 383.8k
Philippe Pouletty	Founder & Director	10.8yrs	€35.00k	0.43% $ 2.8m
Sylvie Gregoire	Chair of the Board	less than a year	데이터 없음	데이터 없음
Christian Trepo	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Lawrence Stanberry	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Troy Ignelzi	Independent Director	1.3yrs	€44.33k	데이터 없음
Christoph Huber	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Claude Bertrand	Member of Scientific Advisory Board	5yrs	€4.94k	데이터 없음
Luc Teyton	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
June Lee	Independent Director	1.3yrs	€35.24k	데이터 없음
Corinna Bonsen-Thomas	Independent Non-Executive Director	7.3yrs	€135.16k	0% $ 0
Ian McGowan	Chairman of Scientific Advisory Board	6.3yrs	데이터 없음	데이터 없음

3.2yrs

평균 재임 기간

63.5yo

평균 연령

경험이 풍부한 이사회: AAVX.F 의 이사회는 경험(평균 재직 기간 3.2 년)으로 간주됩니다.

ABIVAX Société Anonyme 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Abivax SA Announces Board Observer & Advisor Appointments

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax SA Appoints Patrick Malloy as Senior Vice President Investor Relations

ABIVAX Société Anonyme Announces Board Changes

Abivax Appoints Ida Hatoum as Chief People Officer

ABIVAX Société Anonyme, Annual General Meeting, May 05, 2023

Recent updates

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of €150 million.

Abivax SA Announces Board Observer & Advisor Appointments

Abivax SA Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Abivax SA Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25Mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2- Years of Open-Label Maintenance

Abivax SA Provides Updates on Ongoing Clinical Trials

Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax Announces Update to Obefazimod Phase 2B Clinical Development Program in Moderately to Severely Active Crohn’s Disease

Abivax to Host KOL Investor Event to Review Phase 2B Clinical Data and Phase 3 Trial Design for Obefazimod in Patients with Moderately to Severely Active Ulcerative Colitis

ABIVAX Société Anonyme has filed an IPO in the amount of $100 million.

Abivax SA Appoints Patrick Malloy as Senior Vice President Investor Relations

ABIVAX Société Anonyme Announces Board Changes

Abivax Appoints Ida Hatoum as Chief People Officer

ABIVAX Société Anonyme, Annual General Meeting, May 05, 2023

Abivax Receives FDA Agreement on Pediatric Development Plan with Obefazimod in IBD

Abivax Sa Announces First Us Patient Enrolled in Global Phase 3 Program with Obefazimod in Ulcerative Colitis

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax Phase 3 Program with Obefazimod in Ulcerative Colitis Progresses with US IRB Approval

Abivax Reports One-Year Efficacy and Safety Data of Abx464 Phase 2B Maintenance Trial in Ulcerative Colitis

Abivax SA Announces the Detailed Results of the Dose Escalation Phase of Its Clinical Phase 1/2 Study Conducted with ABX196

Abivax SA Receives FDA Feedback with Guidance on Advancing ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis

Abivax Reports Excellent Phase 2A Clinical Safety and Efficacy Results with 50Mg ABX464 in Rheumatoid Arthritis

ABIVAX Société Anonyme Reports Excellent Efficacy and Safety of ABX464 in Phase 2B Clinical Trial in Ulcerative Colitis and Plans to Proceed to Phase 3

Abivax Follows DSMB Recommendation to Stop the Phase 2B/3 Mir-Age Covid-19 Clinical Trial Due to Lack of Efficacy

Abivax Publishes Data of ABX464 Induction and Long-Term Maintenance Phase 2A Ulcerative Colitis Study in the Journal "Gastroenterology"

Abivax Appoints Sophie Biguenet as Chief Medical Officer

Abivax Establishes Clinical, Regulatory and Manufacturing Framework for ABX464 Phase 3 Program and Potential Commercialization in 2021

ABIVAX Société Anonyme to Report First Half, 2021 Final Results on Sep 30, 2021

ABIVAX Société Anonyme to Report First Half, 2021 Results on Sep 23, 2021

Abivax Completes Recruitment of Abx464 Phase 2B Induction Study in Ulcerative Colitis

ABIVAX Société Anonyme has completed a Follow-on Equity Offering in the amount of €27.999994 million.

Abivax Provides an Update on Its Pipeline Progress

ABIVAX SociÃ©tÃ© Anonyme to Report First Half, 2020 Results on Sep 30, 2020

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령